A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Prat, Aleix; Guarneri, Valentina; Paré, Laia; Griguolo, Gaia; Pascual, Tomás; Dieci, Maria Vittoria; Chic, Núria; González-Farré, Blanca; Frassoldati, Antonio; Sanfeliu, Esther; Cejalvo, Juan Miguel; Muñoz, Montserrat; Bisagni, Giancarlo; Brasó-Maristany, Fara; Urso, Loredana; Vidal, María; Brandes, Alba Ariela; Adamo, Bárbara; Musolino, Antonino; Miglietta, Federica; Conte, Benedetta; Oliveira, Mafalda; Saura, Cristina; Pernas, Sònia; Alarcón, Jesús; Llombart-Cussac, Antonio; Cortés, Javier; Manso, Luis; López, Rafael; Ciruelos, Eva; Schettini, Francesco; Villagrasa, Patricia; Carey, Lisa A.; Perou, Charles M.; Piacentini, Federico; D’Amico, Roberto; Tagliafico, Enrico; Parker, Joel S.; Conté, Pierfranco

doi:10.1016/s1470-2045(20)30450-2

Cited by 62 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancers are divided into‐Luminal A, Luminal B, HER2 enriched and basal‐like, which facilitates the adoption of precise treatment strategies and assessment of the prognosis 2 . The prognostic variables, including PAM50 subtypes, gene expression and stromal tumour‐infiltrating lymphocytes, could be used to guide the systemic treatment of breast cancer 3 . Therefore, researchers pay more and more attention to the role of models constructed with multiple variables in the treatment and prognostic of breast cancer patients.F…”

Section: Introductionmentioning

confidence: 99%

Identification of autophagy‐related long non‐coding RNA prognostic signature for breast cancer

Zhu

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Autophagy‐related long non‐coding RNAs (lncRNAs) disorders are related to the occurrence and development of breast cancer. The purpose of this study is to explore whether autophagy‐related lncRNA can predict the prognosis of breast cancer patients. The autophagy‐related lncRNAs prognostic signature was constructed by Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression. We identified five autophagy‐related lncRNAs (MAPT‐AS1, LINC01871, AL122010.1, AC090912.1, AC061992.1) associated with prognostic value, and they were used to construct an autophagy‐related lncRNA prognostic signature (ALPS) model. ALPS model offered an independent prognostic value (HR = 1.664, 1.381‐2.006), where this risk score of the model was significantly related to the TNM stage, ER, PR and HER2 status in breast cancer patients. Nomogram could be utilized to predict survival for patients with breast cancer. Principal component analysis and Sankey Diagram results indicated that the distribution of five lncRNAs from the ALPS model tends to be low‐risk. Gene set enrichment analysis showed that the high‐risk group was enriched in autophagy and cancer‐related pathways, and the low‐risk group was enriched in regulatory immune‐related pathways. These results indicated that the ALPS model composed of five autophagy‐related lncRNAs could predict the prognosis of breast cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of autophagy‐related long non‐coding RNA prognostic signature for breast cancer

Zhu

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Although the death rate of female breast cancer has dropped from its peak by 40% since 1989, the decline rate slowed down in recent years (1). Additionally, some early-stage patients still have worse survival in clinical studies (2,3). A series of studies revealed that age, primary tumor size, tumor location, positive axillary lymph nodes, histological grade, molecular subtype, and BRCA mutation were closely correlated with the prognosis of breast cancer (4)(5)(6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Breast-Conserving Therapy Has Better Prognosis for Tumors in the Central and Nipple Portion of Breast Cancer Compared with Mastectomy: A SEER Data-Based Study

Wang

Zhong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Background and ObjectivesCurrently, the location of primary tumor was an independent prognostic factor of breast cancer. Tumors in the central and nipple portion (TCNP) had poor prognosis compared to other peripheral quadrants. The breast-conserving therapy (BCT) is becoming increasingly common worldwide in breast cancer operations. However, whether the availability of BCT was performed for TCNP remained a matter of debate. We sought to investigate whether BCT was suitable for TCNP with respect to survival outcomes, compared with mastectomy therapy.MethodsUtilizing the Surveillance, Epidemiology, and End Results (SEER) database, we obtained TCNP breast cancer patients diagnosed during the period of 2010–2015. One-to-one (1:1) propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of BCT and mastectomy groups. Univariate and multivariate Cox proportional hazard models were applied to estimate the factors associated with breast cancer-specific survival (BCSS) and overall survival (OS). Survival analysis was performed with the Kaplan–Meier method.ResultsIn the overall cohort, a total of 9,900 patients were enrolled. We found that patients with BCT showed significantly better BCSS (log-rank, p < 0.001) and OS (log-rank, p < 0.001) than the mastectomy group before PSM. The same finding was also shown in 5,820 patients after PSM. Additionally, none of the subgroups, including age, sex, race, histological grade, AJCC stage, and molecular subtype undergoing mastectomy therapy, had better BCSS than BCT.ConclusionsOur study was the first research to show that BCT exhibited superior prognosis in the cohort of TCNP from SEER databases than mastectomy therapy. This finding could provide a cue for treatment strategies for suitable TCNP patients, especially those with a strong willingness to conserve their breasts.

show abstract

“…The HER2DX-combined prognostic score, developed using clinical-pathological data on TILs, PAM50 subtypes and expression of 55 genes in a retrospective analysis of the Short-HER phase III trial, has been used to identify patients with HER2-positive EBC who may be candidates for escalated or de-escalated systemic treatment [85].…”

Section: Future Perspectivesmentioning

confidence: 99%

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge

Jackisch

Cortazar²,

Geyer

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Cited by 62 publications

References 31 publications

Identification of autophagy‐related long non‐coding RNA prognostic signature for breast cancer

Identification of autophagy‐related long non‐coding RNA prognostic signature for breast cancer

Breast-Conserving Therapy Has Better Prognosis for Tumors in the Central and Nipple Portion of Breast Cancer Compared with Mastectomy: A SEER Data-Based Study

Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge

Contact Info

Product

Resources

About